Rhythm Pharmaceuticals Inc.
RYTM - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.59B
Close$
$-23.81
121.5% downside
Current Fair Value
121.5% downsideOvervalued by 121.5% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $7.59 Billion |
|---|---|
| Enterprise Value | $7.43 Billion |
| Earnings per Share | $-3.11 |
| Beta | 2.01 |
| Outstanding Shares | 68,592,661 |
Return
| Return on Equity | -96.97% |
|---|---|
| Return on Assets | -48.19% |
| Return on Invested Capital | -59.90% |
Valuation & Multiples
| P/E Ratio | -29.77 |
|---|---|
| PEG | -520.64 |
| Price to Sales | 36.89 |
| Price to Book Ratio | 36.89 |
| Enterprise Value to Revenue | 30.95 |
| Enterprise Value to EBIT | -39.52 |
| Enterprise Value to Net Income | -36 |
| Total Debt to Enterprise | -0.01 |
| Debt to Equity | -0.46 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 3, 2026
EPS Estimate
$-0.71
Consensus analyst estimateRevenue Estimate
$85.57 M
Consensus analyst estimateNext Earnings Call
Expected Date
February 25, 2027
EPS Estimate
$-0.63
Consensus analyst estimateRevenue Estimate
$106.42 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 58.27% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.86%▼ 112.54% |
|---|---|
| Total Invested | $56.37M▼ 99.35% |
| Investors Holding | 62▼ 251.00% |
About Rhythm Pharmaceuticals Inc.
90 employees
CEO: Hunter Smith
Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for patients living with rare genetic diseases of obesity. Early-onset severe obesity may result from genetic variants within the mel...